| 1 |
34978798 | Development of Photolenalidomide for Cellular Target Identification. | 2022 Jan 12 |
2 |
| 2 |
35583604 | Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL. | 2022 May 18 |
2 |
| 3 |
33563611 | The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. | 2021 Mar |
1 |
| 4 |
34207079 | The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients. | 2021 Jun 18 |
1 |
| 5 |
30026574 | A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. | 2019 Jan |
1 |
| 6 |
28425720 | A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. | 2018 Jan 25 |
1 |
| 7 |
30111438 | [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review]. | 2018 Aug |
1 |
| 8 |
26430725 | Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. | 2015 Oct 2 |
1 |
| 9 |
26438514 | The novel mechanism of lenalidomide activity. | 2015 Nov 19 |
2 |
| 10 |
24206017 | Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. | 2014 Jan |
1 |
| 11 |
24328678 | Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). | 2014 Mar |
4 |